Start with cholangiocarcinoma, then reuse UniProt Q9NRA0 as the stable protein anchor across project notes and exports.
CHEMBL3023 Target Snapshot
Sphingosine kinase 2 · SINGLE PROTEIN · Homo sapiens
Research home keeps recent targets
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Switch target
Move to another high-traffic target or paste a specific ChEMBL target ID.
Frame the target before identity details
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Sphingosine kinase 2 shows clinical signal disease relevance led by cholangiocarcinoma. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q9NRA0. Start with cholangiocarcinoma, then reuse UniProt Q9NRA0 as the stable protein anchor across project notes and exports.
Sphingosine kinase 2 shows clinical signal disease relevance led by cholangiocarcinoma. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with cholangiocarcinoma because it currently carries clinical signal support. Linked drugs include ABC-294640. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxySphingosine kinase 2
Review this target as Sphingosine kinase 2, mapped to UniProt Q9NRA0. Sequence length is 654 aa.
Protein source · UniProt accession via ChEMBL component mappingCross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Sphingosine kinase 2 as ChEMBL target CHEMBL3023, mapped to UniProt Q9NRA0. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Start with the right source
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Sphingosine kinase 2 is the right protein anchor across sources, using UniProt Q9NRA0 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why cholangiocarcinoma is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardBasic Information
Verify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Sphingosine kinase 2 |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | Q9NRA0 |
Next Actions
UniProt Target Context
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Sphingosine kinase 2 |
| UniProt Accession | Q9NRA0 |
| Component Type | Protein |
| Sequence Length | 654 aa |
Sphingosine kinase 2
How to read this target
Review this target as Sphingosine kinase 2, mapped to UniProt Q9NRA0. Sequence length is 654 aa.
Disease Relevance & Evidence Level
Open Targets-ready disease context using the current target-indication evidence contract.
Sphingosine kinase 2 shows clinical signal disease relevance led by cholangiocarcinoma. 5 more disease programs remain visible in the same review block.
How to read disease relevance
Start review with cholangiocarcinoma because it currently carries clinical signal support. Linked drugs include ABC-294640. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Clinical Phase Distribution
Activity Type Distribution
Top Inhibitors (by pChEMBL)
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL4750447 | 10.05 | Ki | 0.09 | Preclinical |
| CHEMBL4782021 | 9.92 | Ki | 0.12 | Preclinical |
| CHEMBL4783605 | 9.54 | Ki | 0.29 | Preclinical |
| CHEMBL4755938 | 9.52 | Ki | 0.3 | Preclinical |
| CHEMBL3814580 | 9.01 | Ki | 0.98 | Preclinical |
| CHEMBL5420859 | 8.72 | IC50 | 1.913 | Preclinical |
| CHEMBL4104017 | 8.62 | IC50 | 2.4 | Preclinical |
| CHEMBL5407736 | 8.62 | IC50 | 2.404 | Preclinical |
| CHEMBL5399307 | 8.46 | IC50 | 3.431 | Preclinical |
| CHEMBL3134157 | 8.44 | Ki | 3.6 | Preclinical |
pChEMBL Value Distribution
Assay Landscape
Binding — 163 assays, 306 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 101 | 128 | 5.8 |
| cell-based format | 48 | 114 | 5.6 |
| assay format | 13 | 63 | 5.3 |
| subcellular format | 1 | 1 | 5.2 |
ADME — 2 assays, 0 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 2 | 0 | — |
Functional — 1 assays, 0 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 1 | 0 | — |